GPCRStructure Therapeutics Inc. American Depositary Shares

ADRCNasdaq (XNAS)·USD

Identity

Security key: 16180
Ticker: GPCR
Type: ADRC — American Depository Receipt Common
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2023-02-03
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: GPCR

Detail

Enriched 2026-08-14 20:47

Market cap: $3,831,627,157.56
Shares outstanding (class): 71,074,516
Shares outstanding (weighted): 71,074,516
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 233
Location: SOUTH SAN FRANCISCO, CA
Homepage: https://www.structuretx.com
Description: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Market cap and share counts drift.

Funds holding this security

75 funds · 79 positions · $359.54M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$61.37M	0.56%	1,273,207 NS	FIGI
Fidelity Contrafund Fidelity Contrafund	—	$37.90M	0.02%	786,405 NS	FIGI
Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND	—	$27.45M	0.53%	569,589 NS	FIGI
Janus Henderson Triton Fund JANUS INVESTMENT FUND	—	$22.15M	0.43%	459,487 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$18.40M	0.23%	381,676 NS	FIGI
Janus Henderson Contrarian Fund JANUS INVESTMENT FUND	—	$15.88M	0.37%	329,472 NS	FIGI
Fidelity Advisor New Insights Fund Fidelity Contrafund	—	$11.96M	0.05%	248,100 NS	FIGI
Janus Henderson Venture Fund JANUS INVESTMENT FUND	—	$11.76M	0.38%	243,999 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$10.02M	0.08%	207,909 NS	FIGI
Fidelity Contrafund K6 Fidelity Contrafund	—	$8.16M	0.02%	169,238 NS	FIGI
abrdn Healthcare Investors —	—	$8.00M	0.70%	166,060 NS	FIGI
VIP Contrafund Portfolio Variable Insurance Products Fund II	—	$7.77M	0.03%	161,200 NS	FIGI
Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust	—	$7.12M	0.08%	147,713 NS	FIGI
Fidelity Series Opportunistic Insights Fund Fidelity Contrafund	—	$6.51M	0.05%	135,000 NS	FIGI
Mid Cap Growth Fund John Hancock Investment Trust	—	$6.34M	0.55%	131,476 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERGPCR
FIGI_COMPOSITEBBG01CBVHLW1
FIGI_SHARE_CLASSBBG01CBVHMQ6
CIK0001888886
ISINUS86366E1064
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: The company is a biopharmaceutical firm focused on developing oral small molecule drugs, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.